Randomized Pilot Study of Supplemental Iscar in Combination With Gemcitabine vs. Gemcitabine Alone as Second Line Treatment for Advanced Non-Small Cell Lung Cancer.
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Non-Small Cell Lung Cancer
Both
Non-Small Cell Lung Cancer
Trial Information
Randomized Pilot Study of Supplemental Iscar in Combination With Gemcitabine vs. Gemcitabine Alone as Second Line Treatment for Advanced Non-Small Cell Lung Cancer.
RAndomized pilot study of supplemental Iscar in combination with Gemcitabine vs. Gemcitabine
alone as second line treatment for advanced non-small cell lung cancer.
Inclusion Criteria:
- newly diagnosed IIIB and IV NSCLC who have failed one prior line of chemo
- Karnofsky score 60% or greater
- patients who will be treated with Gemcitabine
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To determine if Iscar improves immune function and quality of life.
Principal Investigator
Renato V. LaRocca, MD
Investigator Role:
Study Director
Investigator Affiliation:
Kentuckiana Cancer Institute
Authority:
United States: Food and Drug Administration
Study ID:
1056757
NCT ID:
NCT00283478
Start Date:
May 2004
Completion Date:
April 2007
Related Keywords:
- Non-Small Cell Lung Cancer
- Advanced stage
- Lung cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|---|
| Kentuckiana Cancer Institute | Louisville, Kentucky 40202 |
